Last reviewed · How we verify
Amiodarone i.v.
Amiodarone i.v. is a Class III antiarrhythmic agent Small molecule drug developed by Charles University, Czech Republic. It is currently FDA-approved for Atrial fibrillation (acute conversion and maintenance of sinus rhythm), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia. Also known as: Antiarrhythmic therapy.
Amiodarone is a Class III antiarrhythmic that blocks potassium channels to prolong the action potential and refractory period, with additional effects on sodium, calcium, and beta-adrenergic channels.
Amiodarone is a Class III antiarrhythmic that blocks potassium channels to prolong the action potential and refractory period, with additional effects on sodium, calcium, and beta-adrenergic channels. Used for Atrial fibrillation (acute conversion and maintenance of sinus rhythm), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia.
At a glance
| Generic name | Amiodarone i.v. |
|---|---|
| Also known as | Antiarrhythmic therapy |
| Sponsor | Charles University, Czech Republic |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone's primary mechanism involves inhibition of potassium efflux, which lengthens the action potential duration and effective refractory period of cardiac tissue. It also exhibits properties of Class I (sodium channel blockade), Class II (beta-adrenergic antagonism), and Class IV (calcium channel blockade) antiarrhythmics, making it a broad-spectrum agent. This multi-channel activity makes it effective for suppressing both atrial and ventricular arrhythmias.
Approved indications
- Atrial fibrillation (acute conversion and maintenance of sinus rhythm)
- Ventricular tachycardia and ventricular fibrillation
- Supraventricular tachycardia
- Prevention of recurrent arrhythmias in high-risk patients
Common side effects
- Thyroid dysfunction (hypo- or hyperthyroidism)
- Pulmonary toxicity (pneumonitis, fibrosis)
- Hepatotoxicity
- Corneal microdeposits
- Photosensitivity
- Bradycardia
- QT prolongation
- Torsades de pointes
- Nausea and gastrointestinal upset
Key clinical trials
- Propafenone Versus Amiodarone in Septic Shock (PHASE4)
- In-hospital Cardiac Arrest - Dynamics and State Transitions
- Relative Bioavailability of PM101 IV and Cordarone IV (PHASE1)
- Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) (PHASE2, PHASE3)
- Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amiodarone i.v. CI brief — competitive landscape report
- Amiodarone i.v. updates RSS · CI watch RSS
- Charles University, Czech Republic portfolio CI
Frequently asked questions about Amiodarone i.v.
What is Amiodarone i.v.?
How does Amiodarone i.v. work?
What is Amiodarone i.v. used for?
Who makes Amiodarone i.v.?
Is Amiodarone i.v. also known as anything else?
What drug class is Amiodarone i.v. in?
What development phase is Amiodarone i.v. in?
What are the side effects of Amiodarone i.v.?
What does Amiodarone i.v. target?
Related
- Drug class: All Class III antiarrhythmic agent drugs
- Target: All drugs targeting Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels
- Manufacturer: Charles University, Czech Republic — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation (acute conversion and maintenance of sinus rhythm)
- Indication: Drugs for Ventricular tachycardia and ventricular fibrillation
- Indication: Drugs for Supraventricular tachycardia
- Also known as: Antiarrhythmic therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing